uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration.
To examine the effects of the uPA/plasmin system on cell migration in relation to the activation of MMP-9, we used ex vivo and in vitro wound-repair models of human bronchial epithelial cells and videomicroscopy techniques that make possible cell tracking and quantification of cell migration speeds. We observed that uPA was only detected in migrating cells at the wound edges and located at crucial sites for cell/extracellular matrix interactions. The implication of uPA in human bronchial epithelial cell migration was studied by incubating cultures with a monoclonal antibody raised against uPA and these experiments led to a 70% reduction in cell velocity. To examine the effects of the plasmin system on cell migration, we incubated cultures with increasing concentrations of plasmin or activated MMP-9. We observed a significant dose-dependent increase in cell migration velocity with plasmin (P < 0.001) and MMP-9 (P < 0.001). Moreover, addition of exogenous plasmin led to a twofold increase of activated MMP-9 in migrating cells. We also demonstrated that the addition of anti-uPA IgG led to an inhibition of 43% of activated MMP-9. In conclusion, these results show that uPA is involved in human bronchial epithelial cells migration. This action is mediated by the generation of plasmin, which in turn activates MMP-9, thus making possible cell migration.
Legrand
C
C
Laboratoire Pol Bouin-CHU, INSERM Unité 514, IFR 53, and, Reims, France.
Polette
M
M
Tournier
J M
JM
de Bentzmann
S
S
Huet
E
E
Monteau
M
M
Birembaut
P
P
D000911:Antibodies, Monoclonal / Q000378:metabolism; D001980:Bronchi / Q000166:cytology*; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D004789:Enzyme Activation; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism* / Q000494:pharmacology; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D020545:Respiratory Mucosa / Q000166:cytology* / Q000378:metabolism; D013876:Thiophenes / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000276:immunology / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D061965:Matrix Metalloproteinase Inhibitors; D013876:Thiophenes; D010649:Phenylalanine; C080985:batimastat; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator; D020780:Matrix Metalloproteinase 9